<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hormone replacement therapy after surgery for epithelial ovarian cancer - Saeaib, N - 2020 | Cochrane Library</title> <meta content="Hormone replacement therapy after surgery for epithelial ovarian cancer - Saeaib, N - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012559.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hormone replacement therapy after surgery for epithelial ovarian cancer - Saeaib, N - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012559.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012559.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Hormone replacement therapy after surgery for epithelial ovarian cancer" name="citation_title"/> <meta content="Nungrutai Saeaib" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="snungrut@medicine.psu.ac.th" name="citation_author_email"/> <meta content="Krantarat Peeyananjarassri" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="Tippawan Liabsuetrakul" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="Rakchai Buhachat" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="Eva Myriokefalitaki" name="citation_author"/> <meta content="The Christie NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012559.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012559.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012559.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012559.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Hormone Replacement Therapy; Carcinoma, Ovarian Epithelial [*drug therapy, surgery]; Menopause, Premature [drug effects]; Ovarian Neoplasms [*drug therapy, surgery]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012559.pub2&amp;doi=10.1002/14651858.CD012559.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012559\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012559\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","ms","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012559.pub2",title:"Hormone replacement therapy after surgery for epithelial ovarian cancer",firstPublishedDate:"Jan 28, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012559.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012559.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012559.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012559.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012559.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012559.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012559.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012559.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012559.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012559.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9859 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012559.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/appendices#CD012559-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/table_n/CD012559StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/table_n/CD012559StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hormone replacement therapy after surgery for epithelial ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#CD012559-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nungrutai Saeaib</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#CD012559-cr-0003">Krantarat Peeyananjarassri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#CD012559-cr-0004">Tippawan Liabsuetrakul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#CD012559-cr-0005">Rakchai Buhachat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information#CD012559-cr-0006">Eva Myriokefalitaki</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information/en#CD012559-sec-0110">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012559.pub2">https://doi.org/10.1002/14651858.CD012559.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012559-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012559-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012559-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD012559-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012559-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012559-abs-0001" lang="en"> <section id="CD012559-sec-0001"> <h3 class="title" id="CD012559-sec-0001">Background</h3> <p>Women who have undergone surgical treatment for epithelial ovarian cancer (EOC) may develop menopausal symptoms due to immediate loss of ovarian function following surgery and chemotherapy. Women may experience vasomotor symptoms, sleep disturbance, difficulty concentrating, sexual dysfunction, vaginal symptoms and accelerated osteoporosis. Although hormone replacement therapy (HRT) is the most effective treatment to relieve these symptoms, its safety has been questioned for women with EOC. </p> </section> <section id="CD012559-sec-0002"> <h3 class="title" id="CD012559-sec-0002">Objectives</h3> <p>To assess the safety and efficacy of HRT for menopausal symptoms in women surgically treated for EOC. </p> </section> <section id="CD012559-sec-0003"> <h3 class="title" id="CD012559-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 6), MEDLINE via Ovid (1946 to 12 June 2019) and Embase via Ovid (1980 to 2019, week 23). We also handsearched conference reports and trial registries. There was no language restriction. </p> </section> <section id="CD012559-sec-0004"> <h3 class="title" id="CD012559-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) with participants of any age and menopausal status who had undergone surgery for EOC and, after diagnosis and treatment, used any regimen and duration of HRT compared with placebo or no hormone therapy. We also included trials comparing different regimens or duration of administration of HRT. </p> </section> <section id="CD012559-sec-0005"> <h3 class="title" id="CD012559-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified studies that met the inclusion criteria. They used Covidence to extract study characteristics, outcome data and to assess methodological quality of the included studies<i><b>.</b> </i> </p> </section> <section id="CD012559-sec-0006"> <h3 class="title" id="CD012559-sec-0006">Main results</h3> <p>Our search strategy identified 2617 titles, of which 2614 titles were excluded. Three studies, involving 350 women, met our inclusion criteria. Two of the studies included pre and postmenopausal women, and the third only included premenopausal women. The overall age range of those women included in the studies was 20 to 89.6 years old, with a median follow‐up ranging from 31.4 months to 19.1 years. The geographical distribution of participants included Europe, South Africa and China. All stages and histological subtypes were included in two of the studies, but stage IV disease had been excluded in the third. The three included studies used a variety of HRT regimens (conjugated oestrogen with or without medroxyprogesterone and with or without nylestriol) and HRT administrations (oral, patch and implant), In all studies, the comparisons were made versus women who had not received HRT. </p> <p>The studies were at low or unclear risk of selection and reporting bias, and at high risk of performance, detection and attrition bias<b><i>.</i> </b> The certainty of the evidence was low for overall survival and progression‐free survival, and very low for quality‐of‐life assessment, incidence of breast cancer, transient ischaemic attack (TIA), cerebrovascular accident (CVA) and myocardial infarction (MI). </p> <p>Meta‐analysis of these studies showed that HRT may improve overall survival (hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.54 to 0.93; 350 participants, 3 studies; low‐certainty evidence). Quality‐of‐life assessment by use of the EORTC‐C30 questionnaire was performed only in one study. We are uncertain whether HRT improves or reduces quality of life as the certainty of the evidence was assessed as very low (mean difference (MD) 13.67 points higher, 95% CI 9.26 higher to 18.08 higher; 1 study; 75 participants; very low‐certainty evidence). Likewise, HRT may make little or no difference to progression‐free survival (HR 0.76, 95% CI 0.57 to 1.01; 275 participants, 2 studies; low‐certainty evidence). </p> <p>We are uncertain whether HRT improves or reduces the incidence of breast cancer (risk ratio (RR) 2.00, 95% CI 0.19 to 21.59; 225 participants, 2 studies; very low‐certainty evidence); TIA (RR 5.00, 95% CI 0.24 to 102.42; 150 participants, 1 study; very low‐certainty evidence); CVA (RR 0.67, 95% CI 0.11 to 3.88; 150 participants, 1 study; very low‐certainty evidence); and MI (RR 0.20, 95% CI 0.01 to 4.10; 150 participants, 1 study; very low‐certainty evidence). The incidence of gallstones was not reported in the included studies. </p> </section> <section id="CD012559-sec-0007"> <h3 class="title" id="CD012559-sec-0007">Authors' conclusions</h3> <p>Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression‐free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well‐designed RCTs are required as this is an important area to women experiencing menopausal symptoms following surgical treatment for ovarian cancer, especially as doctors are often reluctant to prescribe HRT in this scenario. The evidence in this review is too limited to support or refute that HRT is very harmful in this population. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012559-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012559-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012559-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012559-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD012559-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012559-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012559-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012559-abs-0005" lang="en"> <h3>Hormone replacement therapy for menopausal symptoms in women who have undergone surgical treatment for epithelial ovarian cancer </h3> <p><b>The issue</b> <br/> Epithelial ovarian cancer (EOC) develops from the surface layer of the ovary. It is the eighth most common cancer and the seventh most common cause of death from cancer worldwide in women. The surgical treatment of EOC includes the removal of all visible tumour deposits in the abdomen; this usually includes both ovaries, the uterus (womb), omentum (fatty curtain that hangs from the stomach and transverse colon), and peritoneum, with or without the removal of lymph nodes or other organs. Women who were premenopausal before the procedure go on to experience the menopause as a result of the surgery. This may negatively affect their quality of life due to symptoms such as hot flushes, mood swings, change of sexual activity, vaginal dryness and loss of bone density. Around a quarter of women, especially younger women, will present with early‐stage disease and will be left with long‐term adverse health effects of a surgically induced menopause. In those women with advanced disease at diagnosis, quality of life is an important factor to consider, as their disease is life‐limiting. </p> <p>Hormone replacement therapy (HRT) might be effective for postmenopausal symptoms, but there are serious concerns around the safety of this treatment. These concerns are not just related to cancer, but also to the heart, and they need to be balanced against the positive health effects of HRT for women with an early menopause. In recent years the safety of HRT has been questioned and doctors may be cautious in prescribing HRT for women who are experiencing surgically‐induced menopause after treatment for EOC. </p> <p><b>The aim of the review</b><br/> To assess the safety and efficacy of hormone replacement therapy (HRT) for menopausal symptoms in women treated surgically for EOC. </p> <p><b>What were the main findings?</b><br/> We searched for evidence of benefits and harms of HRT in EOC, up to June 2019. We identified three studies involving a total of 350 women. We found that HRT may improve overall survival and may make little or no difference to progression‐free survival. We are unsure about the effects on quality of life, incidence of breast cancer, transient ischaemic attack (also known as 'mini stroke'), cerebrovascular accident (stroke) and myocardial infarction (heart attack), as the certainty of the evidence was very low. There were no reports on the incidence of gallstones. </p> <p><b>Quality of the evidence</b><br/> The certainty of the evidence was low to very low for all outcomes, mainly due to the small number of participants and low numbers of adverse events reported. The certainty of the evidence is also reduced due to the high risk of bias of the included studies, meaning their results might overestimate or underestimate the true effect of the treatment. </p> <p><b>What were the conclusions?</b> <br/> Hormone replacement therapy may improve the overall survival in women who are experiencing surgically induced menopause after treatment for EOC, but it may make little or no difference to survival without the disease getting worse. The overall certainty of these findings is low to very low, mainly due to a lack of information. This is a very important area for further research, which has the potential to make a big impact on many women. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012559-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-sec-0100">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-sec-0153">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012559-sec-0100"></div> <h3 class="title" id="CD012559-sec-0101">Implications for practice</h3> <section id="CD012559-sec-0101"> <p>Hormone replacement therapy (HRT) may improve overall survival in women who have undergone surgery for epithelial ovarian cancer (EOC). However, this is based on low‐certainty evidence and therefore should be interpreted with caution. We are very uncertain about the impact of HRT on progression‐free survival and incidence of adverse events such as breast cancer, transient ischaemic accident, cerebrovascular accident and myocardial infarction. The incidence of gallstones was not reported in any of the included studies. The evidence in this review is too limited to support or refute that HRT is very harmful in this population. Women and their doctors should therefore make decisions based on individual priorities and symptoms. </p> </section> <h3 class="title" id="CD012559-sec-0102">Implications for research</h3> <section id="CD012559-sec-0102"> <p>Menopause can be the cause of severe symptoms. There is a lot of concern and confusion surrounding the use of HRT, due to the fear of potential risks and menopausal symptoms, and it is often neglected as clinicians are more likely to focus on cancer treatment and survival outcomes. Therefore, future well‐designed randomized controlled trials (RCTs) investigating the risks and benefits of HRT use in women treated for EOC and surgically induced menopause would be welcomed. These studies should have larger sample sizes and longer follow‐up of women with EOC and should look at both survival and quality‐of‐life outcomes. Future research should consider the age of women, duration of HRT use, hormone receptors status and BRCA mutation status. Moreover, specific measurements for quality‐of‐life assessments regarding menopausal symptoms should be mandated in future studies. This is significant for women with good prognosis, who may have a premature surgically induced menopause and subsequent health problems. It is also important for women with more advanced disease in whom quality of life is often overlooked, as the main focus is on cancer treatment and survival outcomes. Given that many of these women have life‐limiting disease, treatments that so far appear to have limited deleterious effect on survival, but may have significant effect on their well‐being, deserve more attention. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012559-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012559-sec-0036"></div> <div class="table" id="CD012559-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone replacement therapy (HRT) compared to no HRT for women who have undergone surgery for epithelial ovarian cancer (EOC)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hormone replacement therapy (HRT) compared to no HRT for epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patients:</b> women of any age diagnosed with any stage of EOC who had surgical treatment, regardless of chemotherapy treatment<br/> <b>Setting:</b> multiple centres in the United Kingdom, Spain and Hungary, and single institutes in South Africa and China<br/> <b>Intervention:</b> HRT; oestrogen‐alone, and oestrogen combined with progestin, oestrogen agonist/antagonist, testosterone or tibolone in any dose and any route of administration<br/> <b>Comparison:</b> no HRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no HRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.71<br/> (0.54 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>350<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the three included studies was 31.4 months, 90 months and 19.1 years. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>795 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1,000<br/> (575 to 771) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life, general condition</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean quality of life (general condition) in the no HRT group was 13.84 points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean quality of life (general condition) in the HRT group was 13.67 points higher<br/> (9.26 higher to 18.08 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The EORTC‐C30 questionnaire was used to evaluate this outcome; higher values correspond with improvement. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/> (0.57 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the two studies was 90 months and 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>773 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>676 per 1,000<br/> (571 to 776) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of breast cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/> (0.19 to 21.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the two studies was 31.41 months and 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1,000<br/> (2 to 181) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of transient ischaemic attack</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.24 to 102.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (2 to 683) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of cerebrovascular accident</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.11 to 3.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000<br/> (4 to 155) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.01 to 4.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000<br/> (0 to 109) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of gallstones</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of gallstones was not reported in the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; HR: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to limitations in study design<br/> <sup>2</sup> Downgraded by one level due to inconsistency of results<br/> <sup>3</sup> Downgraded by one level due to imprecision of results<br/> <sup>4</sup> Downgraded by two levels due to imprecision of results </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012559-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-sec-0118">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012559-sec-0037"></div> <section id="CD012559-sec-0038"> <h3 class="title" id="CD012559-sec-0038">Description of the condition</h3> <p>One in 70 women will develop ovarian cancer (<a href="./references#CD012559-bbs2-0021" title="FlemingG , SeidmanJ , LengyelE . Epithelial ovarian cancer. In: BarakatRR , BerchuckA , MarkmanM , RandallME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2013:757‐847. ">Fleming 2013</a>) and its age‐standardized incidence rate (ASR) is 6.6 per 100,000 women (<a href="./references#CD012559-bbs2-0022" title="International Agency for Research on Cancer and World Health Organization. Cancer Today. Estimated age‐standardized incidence rates (World) in 2018, worldwide, both sexes, all ages. Available from https://gco.iarc.fr/today (accessed 6 January 2019). ">GLOBOCAN 2018</a>). This is lower in Western Africa and higher in Northern Europe, varying from 3 to 13 per 100,000) (<a href="./references#CD012559-bbs2-0021" title="FlemingG , SeidmanJ , LengyelE . Epithelial ovarian cancer. In: BarakatRR , BerchuckA , MarkmanM , RandallME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2013:757‐847. ">Fleming 2013</a>). One in 100 women will die of the disease (<a href="./references#CD012559-bbs2-0021" title="FlemingG , SeidmanJ , LengyelE . Epithelial ovarian cancer. In: BarakatRR , BerchuckA , MarkmanM , RandallME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2013:757‐847. ">Fleming 2013</a>) and the ASR of mortality is 3.9 per 100,000 (<a href="./references#CD012559-bbs2-0022" title="International Agency for Research on Cancer and World Health Organization. Cancer Today. Estimated age‐standardized incidence rates (World) in 2018, worldwide, both sexes, all ages. Available from https://gco.iarc.fr/today (accessed 6 January 2019). ">GLOBOCAN 2018</a>). The median age at diagnosis of epithelial ovarian cancer (EOC) is 60 years (<a href="./references#CD012559-bbs2-0042" title="Michaelson‐CohenR , BellerU . Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology2009;21(5):407‐11. ">Michaelson‐Cohen 2009</a>). However, 40% of women affected are 30 to 60 years old and 3% to 17% are less than 40 years old (<a href="./references#CD012559-bbs2-0027" title="IbeanuO , ModesittSC , DucieJ , vonGruenigenV , AguehM , FaderAN . Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology2011;122(2):447‐54. ">Ibeanu 2011</a>; <a href="./references#CD012559-bbs2-0042" title="Michaelson‐CohenR , BellerU . Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology2009;21(5):407‐11. ">Michaelson‐Cohen 2009</a>; <a href="./references#CD012559-bbs2-0057" title="WenY , HuangH , WuM , ShenK , PanL . The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric2013;16(6):673‐81. ">Wen 2013</a>). The majority of women with EOC (60% to 75%) have advanced stage disease at presentation and the overall five‐year survival for all stages is 45% (<a href="./references#CD012559-bbs2-0027" title="IbeanuO , ModesittSC , DucieJ , vonGruenigenV , AguehM , FaderAN . Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology2011;122(2):447‐54. ">Ibeanu 2011</a>; <a href="./references#CD012559-bbs2-0054" title="SinghP , OehlerMK . Hormone replacement after gynaecological cancer. Maturitas2010;65(3):190‐7. ">Singh 2010</a>). </p> <p>Debulking (removal) of any visible tumour (also known as cytoreductive surgery) is standard surgery for disease staging and treatment; it includes hysterectomy, bilateral salpingo‐oophorectomy and omentectomy with or without pelvic and para‐aortic lymphadenectomy (i.e. the removal of all visible lesions in the abdomen and pelvic cavity including the ovaries, uterus (womb) and omentum (fatty curtain that hangs from the stomach/transverse colon), with or without lymph nodes) (<a href="./references#CD012559-bbs2-0021" title="FlemingG , SeidmanJ , LengyelE . Epithelial ovarian cancer. In: BarakatRR , BerchuckA , MarkmanM , RandallME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2013:757‐847. ">Fleming 2013</a>). In young women with early‐stage disease or disease present in only in one ovary, fertility‐sparing surgery (where only the affected ovary is removed) may be appropriate. Removal of the remaining ovary is recommended once the woman has completed her family. Bilateral oophorectomy (the surgical removal of both ovaries), and the consequent the loss of ovarian function in premenopausal women, induces an immediate surgical menopause and may result in a range of symptoms including vasomotor symptoms, sleep depravation, difficulty with concentration, sexual dysfunction, vaginal symptoms and accelerated osteoporosis (<a href="./references#CD012559-bbs2-0014" title="BiliatisI , ThomakosN , RodolakisA , AkrivosN , ZacharakisD , AntsaklisA . Safety of hormone replacement therapy in gynaecological cancer survivors. Journal of Obstetrics and Gynaecology2012;32:321‐5. ">Biliatis 2012</a>; <a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>). Symptoms following a surgical menopause in younger women may be more intense than in the natural menopause because of sudden onset (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>; <a href="./references#CD012559-bbs2-0054" title="SinghP , OehlerMK . Hormone replacement after gynaecological cancer. Maturitas2010;65(3):190‐7. ">Singh 2010</a>; <a href="./references#CD012559-bbs2-0057" title="WenY , HuangH , WuM , ShenK , PanL . The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric2013;16(6):673‐81. ">Wen 2013</a>). </p> <p>Studies have demonstrated that the origin of many high‐grade (HG) serous EOCs (and primary peritoneal cancer), the most common histological sub‐type of EOC, may be the fimbrial end of the fallopian tube (<a href="./references#CD012559-bbs2-0030" title="LeeperK , GarciaR , SwisherE , GoffB , GreerB , PaleyP . Pathologic findings in prophylactic oophorectomy specimens in high‐risk women. Gynecologic Oncology2002;87(1):52‐6. ">Leeper 2002</a>). In this review, we use the terms 'EOC' and 'ovarian cancer' as umbrella terms to include primary peritoneal and fallopian tube HG serous cancers. </p> </section> <section id="CD012559-sec-0039"> <h3 class="title" id="CD012559-sec-0039">Description of the intervention</h3> <p>Hormone replacement therapy is the delivery of hormones, usually oestrogen with or without progesterone, to replace the normal ovarian production of hormones either due to ovarian failure (chemotherapy‐induced menopause) or after surgical removal of both ovaries (surgically induced menopause). HRT can be administrated in a variety of formulations and doses. It can be taken orally, vaginally, intranasally, as an implant, skin patch, cream or gel. The administration of HRT can be continuous (every day), sequential (for part of each month) or less frequently (<a href="./references#CD012559-bbs2-0039" title="MarjoribanksJ , FarquharC , RobertsH , LethabyA . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4] ">Marjoribanks 2012</a>). HRT can relieve menopausal symptoms and prevent heart disease and osteoporosis (<a href="./references#CD012559-bbs2-0027" title="IbeanuO , ModesittSC , DucieJ , vonGruenigenV , AguehM , FaderAN . Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology2011;122(2):447‐54. ">Ibeanu 2011</a>). However, HRT may have an effect on blood lipids levels and cause headaches, bloationg and breast tenderness (<a href="./references#CD012559-bbs2-0039" title="MarjoribanksJ , FarquharC , RobertsH , LethabyA . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4] ">Marjoribanks 2012</a>). </p> <p>For women with a uterus, progesterone is required to prevent endometrial hyperplasia and malignancy. Women without a uterus can be given oestrogen‐only HRT. Combined continuous HRT — consisting of an oestrogen and a progestogen, taken daily without a break — can increase the risk of coronary events, venous thromboembolism, stroke, breast cancer, gallstones and death from lung cancer (<a href="./references#CD012559-bbs2-0039" title="MarjoribanksJ , FarquharC , RobertsH , LethabyA . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4] ">Marjoribanks 2012</a>). However, oestrogen‐only HRT following hysterectomy has not been shown to increase the incidence of breast cancer (<a href="./references#CD012559-bbs2-0016" title="ChlebowskiRT , RohanTE , MansonJE , AragakiAK , KaunitzA , StefanickML , et al. Breast cancer after use of estrogen plus progestin and estrogen alone; analyses of data from 2 Women's Health Initiative randomized clinical trials. Journal of the American Medical Association2015;1(3):296‐305. ">Chlebowski 2015</a>; <a href="./references#CD012559-bbs2-0039" title="MarjoribanksJ , FarquharC , RobertsH , LethabyA . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4] ">Marjoribanks 2012</a>). </p> </section> <section id="CD012559-sec-0040"> <h3 class="title" id="CD012559-sec-0040">How the intervention might work</h3> <p>Hormone replacement therapy (HRT) is a very effective treatment for the management of menopausal symptoms and the prevention of heart disease and osteoporosis (<a href="./references#CD012559-bbs2-0027" title="IbeanuO , ModesittSC , DucieJ , vonGruenigenV , AguehM , FaderAN . Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology2011;122(2):447‐54. ">Ibeanu 2011</a>). However, the effect of hormones is also dependent on the availability of oestrogen and progesterone receptors. Oestrogen and progesterone are mainly included in the regimen given to women experiencing menopausal symptoms. Oestrogens have an important role in reproductive development, bone homeostasis, cardiovascular remodelling and brain function (<a href="./references#CD012559-bbs2-0026" title="HuaH , ZhangH , KongQ , JiangY . Mechanisms for estrogen receptor expression in human cancer. Experimental Hematology &amp; Oncology2018;7(24):1‐11. ">Hua 2018</a>). Oestrogen has a role in cancer through binding with two types of oestrogen receptors (ER), namely ERα (an oncogene) and ERβ (a tumour suppressor gene which can be expressed in 40% to 60% of ovarian tumours) (<a href="./references#CD012559-bbs2-0026" title="HuaH , ZhangH , KongQ , JiangY . Mechanisms for estrogen receptor expression in human cancer. Experimental Hematology &amp; Oncology2018;7(24):1‐11. ">Hua 2018</a>). However, a meta‐analysis did not show any prognostic effect of ER levels on survival in women with ovarian cancer (<a href="./references#CD012559-bbs2-0058" title="ZhaoD , ZhangF , ZhangW , HeJ , ZhaoY , SunJ . Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta‐analysis. International Journal of Gynecological Cancer2013;23(1):25‐33. ">Zhao 2013</a>). It has been shown that progesterone and progesterone receptors (PRs) interact with oestrogen in order to promote a proliferative and pro‐survival response in breast cells. Conversley, progesterone inhibits the oestrogen‐driven growth in the uterus and ovary and protects the ovary from neoplastic transformation (<a href="./references#CD012559-bbs2-0019" title="DiepCH , DanielAR , MauroLJ , KnutsonTP , LangeCA . Progesterone action in breast, uterine, and ovarian cancers. Journal of Molecular Endocrinology2015;54(2):R31‐53. ">Diep 2015</a>); it has also been shown to have a significant association with survival (<a href="./references#CD012559-bbs2-0035" title="LuoH , LiS , ZhaoM , ShengB , ZhuH , ZhuX . Prognostic value of progesterone receptor expression in ovarian cancer: a meta‐analysis. Oncotarget2017;8(22):36845‐56. ">Luo 2017</a>; <a href="./references#CD012559-bbs2-0058" title="ZhaoD , ZhangF , ZhangW , HeJ , ZhaoY , SunJ . Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta‐analysis. International Journal of Gynecological Cancer2013;23(1):25‐33. ">Zhao 2013</a>). BRCA1 and BRCA2 are oncosuppressor genes which, when mutated, increase the lifetime risk of developing breast cancer to between 45% and 80% and ovarian and fallopian tubal cancers to between 15% and 56%. This compares with a general population lifetime risk of developing ovarian cancer of 2% to 3% (<a href="./references#CD012559-bbs2-0038" title="MarchettiC , IadarolaR , PalaiaI , diDonatoV , PerniolaG , MuziiL , et al. Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause2013;21(7):763‐8. ">Marchetti 2013</a>), although those with BRCA germline mutations have a significantly improved overall survival compared to non‐BRCA mutation carriers (<a href="./references#CD012559-bbs2-0059" title="ZhongQ , PengHL , ZhaoX , ZhangL , HwangWT . Effects of BRCA1‐ and BRCA2‐related mutations on ovarian and breast cancer survival: a meta‐analysis. Clinical Cancer Research2015;21(1):211‐20. ">Zhong 2015</a>). However, women with breast cancer who are BRCA1 (but not BRCA2) mutation carriers have significantly poorer survival (<a href="./references#CD012559-bbs2-0059" title="ZhongQ , PengHL , ZhaoX , ZhangL , HwangWT . Effects of BRCA1‐ and BRCA2‐related mutations on ovarian and breast cancer survival: a meta‐analysis. Clinical Cancer Research2015;21(1):211‐20. ">Zhong 2015</a>). </p> <p>Hormone replacement therapy has been associated with angiogenesis (<a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>) that may stimulate residual ovarian cancer cells of either microscopic or visible disease in women treated for EOC or induce new hormone‐dependent diseases, such as breast cancer (<a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>; <a href="./references#CD012559-bbs2-0054" title="SinghP , OehlerMK . Hormone replacement after gynaecological cancer. Maturitas2010;65(3):190‐7. ">Singh 2010</a>). For these reasons, clinicians may be cautious in prescribing HRT for menopausal symptoms in women after surgery for EOC. Benefits in quality of life for each individual therefore have to be weighed against any theoretical risks. However, the prognosis of early‐stage EOC is good, with a low incidence of recurrence and mortality (less than 10% of women with recurrent disease in stage I EOC) (<a href="./references#CD012559-bbs2-0034" title="LoweKA , ChiaVM , TaylorA , O'MalleyC , KelshM , MohamedM , et al. An international assessment of ovarian cancer incidence and mortality. Gynecologic Oncology2013;130(1):107‐14. ">Lowe 2013</a>) and prolonged survival. Due to these reasons, the risks of premature menopause, including osteoporosis, cardiovascular disease, venous thromboembolic disease and stroke, may outweigh the risk of HRT use. Advanced stage EOC has a poor prognosis with a higher incidence of recurrence and mortality (rate greater than 90% for stage IV) (<a href="./references#CD012559-bbs2-0034" title="LoweKA , ChiaVM , TaylorA , O'MalleyC , KelshM , MohamedM , et al. An international assessment of ovarian cancer incidence and mortality. Gynecologic Oncology2013;130(1):107‐14. ">Lowe 2013</a>) and five‐year overall survival of less than 25% to 30% (<a href="./references#CD012559-bbs2-0013" title="BigliaN , BounousVE , SgroLG , D’AlonzoM , GalloM . Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas2015;82(3):296‐8. ">Biglia 2015</a>; <a href="./references#CD012559-bbs2-0027" title="IbeanuO , ModesittSC , DucieJ , vonGruenigenV , AguehM , FaderAN . Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology2011;122(2):447‐54. ">Ibeanu 2011</a>). Quality‐of‐life outcomes are therefore important for both those with early‐ and late‐stage disease. </p> <p>Hormone replacement therapy can relieve menopausal symptoms among women with early‐stage ovarian cancer and improve the quality of life of those with advanced‐stage disease (<a href="./references#CD012559-bbs2-0011" title="Ursic‐VrscajM , BebarS , ZakeljMP . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause2001;8(1):70‐5. ">Ursic‐Vrscaj 2001</a>). Three retrospective studies have shown that HRT use was not associated with an increase in overall survival and tumour recurrence or a trend to decreased mortality (<a href="./references#CD012559-bbs2-0020" title="EelesRA , TanS , WiltshawE , FryattI , A'HernRP , ShepherdJH , et al. Hormone replacement therapy and survival after surgery for ovarian cancer. British Medical Journal1991;302:259‐62. ">Eeles 1991</a>; <a href="./references#CD012559-bbs2-0011" title="Ursic‐VrscajM , BebarS , ZakeljMP . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause2001;8(1):70‐5. ">Ursic‐Vrscaj 2001</a>; <a href="./references#CD012559-bbs2-0057" title="WenY , HuangH , WuM , ShenK , PanL . The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric2013;16(6):673‐81. ">Wen 2013</a>). In one study, women with serous type ovarian cancer who received HRT achieved better overall survival (<a href="./references#CD012559-bbs2-0040" title="MascarenhasC , LambeM , BelloccoR , BergfeldtK , RimanT , PerssonI , et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer2006;119(12):2907‐15. ">Mascarenhas 2006</a>). In addition, two small randomized controlled trials (RCTs) showed no adverse effects of HRT on survival (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). Conversely, studies of HRT use in women with no type of cancer have shown an increased risk of developing ovarian cancer (<a href="./references#CD012559-bbs2-0060" title="ZhouB , SunQ , CongR , GuH , TangN , YangL , et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology2008;108(3):641‐51. ">Zhou 2008</a>). Therefore, the effectiveness of HRT on overall survival of women with ovarian cancer remains unclear. </p> </section> <section id="CD012559-sec-0041"> <h3 class="title" id="CD012559-sec-0041">Why it is important to do this review</h3> <p>In recent years the safety of HRT has been questioned. This has led to fewer women taking HRT, with the consequence that more women experience menopausal symptoms and the long‐term effects of menopause. Premenopausal women affected by ovarian cancer who have both ovaries removed experience an acute surgically or chemotherapy‐induced menopause, which can lead to more prominent menopausal symptoms. Disease‐specific survival is better for younger women compared to older women (age at diagnosis 30 years or younger, versus 30 to 60 years and 60 years or older) (<a href="./references#CD012559-bbs2-0021" title="FlemingG , SeidmanJ , LengyelE . Epithelial ovarian cancer. In: BarakatRR , BerchuckA , MarkmanM , RandallME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2013:757‐847. ">Fleming 2013</a>). Therefore a younger population of women are longer‐term survivors of EOC and are more likely to experience an early and possibly more symptomatic menopause (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>; <a href="./references#CD012559-bbs2-0054" title="SinghP , OehlerMK . Hormone replacement after gynaecological cancer. Maturitas2010;65(3):190‐7. ">Singh 2010</a>; <a href="./references#CD012559-bbs2-0057" title="WenY , HuangH , WuM , ShenK , PanL . The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric2013;16(6):673‐81. ">Wen 2013</a>). </p> <p>Hormone replacement therapy may be helpful for treatment of menopausal symptoms, but a meta‐analysis of cohort and case‐control studies showed increase risk of developing ovarian cancer in women not previously diagnosed with ovarian cancer who were on HRT for more than 10 years (<a href="./references#CD012559-bbs2-0060" title="ZhouB , SunQ , CongR , GuH , TangN , YangL , et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology2008;108(3):641‐51. ">Zhou 2008</a>). There have been three systematic reviews looking into the use of HRT in ovarian cancer after surgery (<a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>; <a href="./references#CD012559-bbs2-0032" title="LiD , DingC‐y , QiuL‐h . Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology2015;139(2):355‐62. ">Li 2015</a>; <a href="./references#CD012559-bbs2-0046" title="PergialiotisV , PitsouniE , ProdromidouA , FrountzasM , PerreaDN , VlachosGD . Hormone therapy for ovarian cancer survivors: systematic review and meta‐analysis. Menopuase2015;23(3):335‐42. ">Pergialiotis 2015</a>). The first systematic review included one RCT (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>) and two observational studies (<a href="./references#CD012559-bbs2-0020" title="EelesRA , TanS , WiltshawE , FryattI , A'HernRP , ShepherdJH , et al. Hormone replacement therapy and survival after surgery for ovarian cancer. British Medical Journal1991;302:259‐62. ">Eeles 1991</a>; <a href="./references#CD012559-bbs2-0011" title="Ursic‐VrscajM , BebarS , ZakeljMP . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause2001;8(1):70‐5. ">Ursic‐Vrscaj 2001</a>) and suggested that HRT was acceptable as supportive and symptomatic therapy and did not affect overall survival and disease‐free survival (<a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>). The second and third systematic reviews (in which the last search was conducted in March 2015) included four cohort studies (<a href="./references#CD012559-bbs2-0020" title="EelesRA , TanS , WiltshawE , FryattI , A'HernRP , ShepherdJH , et al. Hormone replacement therapy and survival after surgery for ovarian cancer. British Medical Journal1991;302:259‐62. ">Eeles 1991</a>; <a href="./references#CD012559-bbs2-0040" title="MascarenhasC , LambeM , BelloccoR , BergfeldtK , RimanT , PerssonI , et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer2006;119(12):2907‐15. ">Mascarenhas 2006</a>; <a href="./references#CD012559-bbs2-0011" title="Ursic‐VrscajM , BebarS , ZakeljMP . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause2001;8(1):70‐5. ">Ursic‐Vrscaj 2001</a>; <a href="./references#CD012559-bbs2-0057" title="WenY , HuangH , WuM , ShenK , PanL . The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric2013;16(6):673‐81. ">Wen 2013</a>) and two RCTs (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>), and showed a favourable impact of HRT on overall survival, without increasing the risk of recurrence (<a href="./references#CD012559-bbs2-0032" title="LiD , DingC‐y , QiuL‐h . Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology2015;139(2):355‐62. ">Li 2015</a>; <a href="./references#CD012559-bbs2-0046" title="PergialiotisV , PitsouniE , ProdromidouA , FrountzasM , PerreaDN , VlachosGD . Hormone therapy for ovarian cancer survivors: systematic review and meta‐analysis. Menopuase2015;23(3):335‐42. ">Pergialiotis 2015</a>). </p> <p>The aim of this Cochrane review is to investigate the safety of HRT in women experiencing surgically induced menopause, both from the oncological perspective (recurrence and survival) and also in terms of quality of life. We hope that this review will facilitate counselling and informed decision making by women who seek advice and management following their cancer treatment and early and acute menopause. Currently, there is no clear evidence and opinions are conflicting. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012559-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-sec-0123">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012559-sec-0042"></div> <p>To assess the safety and efficacy of hormone replacement therapy (HRT) for menopausal symptoms in women surgically treated for epithelial ovarian cancer (EOC). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012559-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-sec-0124">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012559-sec-0043"></div> <section id="CD012559-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012559-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) (excluding cluster‐randomized or cross‐over trials) comparing HRT of any regimen and duration of administration versus placebo or no hormone therapy, or trials comparing different regimens or duration of administration of HRT. </p> </section> <section id="CD012559-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included women of any age who were diagnosed with any stage of EOC and had surgical treatment, regardless of chemotherapy treatment. </p> </section> <section id="CD012559-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We included studies of HRT used after treatment for EOC. We did not study the aetiological effect of HRT used before diagnosis. We included any HRT (oestrogen alone or combined with progestin, oestrogen agonist/antagonist, progestin, or testosterone, and tibolone), of any regimen or duration of administration, compared with placebo or no hormone therapy. Due to pharmacokinetic differences between different regimens and durations of administration, we investigated the following three comparisons. </p> <p> <ol id="CD012559-list-0001"> <li> <p>HRT versus placebo or no HRT</p> </li> <li> <p>Different regimens of HRT</p> </li> <li> <p>Different durations of HRT administration</p> </li> </ol> </p> </section> <section id="CD012559-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD012559-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012559-list-0002"> <li> <p>Overall survival: survival until death from all causes; survival was assessed from time of enrolment in the study. </p> </li> <li> <p>Quality of life: defined as an individual's perception of life in the context of the culture and value systems (which also includes specific menopausal symptoms like hot flushes, night sweats, vaginal dryness, etc.) measured by any validated scale or questionnaire for quality of life. </p> </li> </ol> </p> </section> <section id="CD012559-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012559-list-0003"> <li> <p>Progression‐free survival: survival until progression of disease. Survival was assessed from the time of enrolment in the study. </p> </li> <li> <p>Adverse events</p> <ol id="CD012559-list-0004"> <li> <p>Incidence of breast cancer</p> </li> <li> <p>Thromboembolic events (pulmonary embolism (PE), deep vein thrombosis (DVT), coronary event, myocardial infarction (MI), stroke, transient ischaemic accident (TIA), cerebrovascular accident (CVA) </p> </li> <li> <p>Gallstones</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD012559-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>In consultation with the Cochrane Gynaecological, Neuro‐oncology and Orphan Cancers Information Specialists, we searched for papers published in any language. When necessary, papers would have been translated. </p> <section id="CD012559-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases on 12 June 2019:</p> <p> <ul id="CD012559-list-0005"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 6), in the Cochrane library (<a href="./appendices#CD012559-sec-0106">Appendix 1</a>) </p> </li> <li> <p>MEDLINE via Ovid (1946 to 12 June 2019) (<a href="./appendices#CD012559-sec-0107">Appendix 2</a>) </p> </li> <li> <p>Embase via Ovid (1980 to 2019 week 23) (<a href="./appendices#CD012559-sec-0108">Appendix 3</a>) </p> </li> </ul> </p> </section> <section id="CD012559-sec-0053"> <h4 class="title">Searching other resources</h4> <p>All relevant articles were identified on PubMed and using the 'related articles' feature; a further search was carried out for newly published articles. We searched the following registries for ongoing trials. </p> <p> <ul id="CD012559-list-0006"> <li> <p>Metaregister (<a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled‐trials.com/rct</a>) </p> </li> <li> <p>Physicians Data Query (<a href="https://www.cancer.gov/publications/pdq" target="_blank">www.cancer.gov/publications/pdq</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) </p> </li> <li> <p>ClinicalTrails.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) </p> </li> <li> <p>National Cancer Institute (<a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" target="_blank">www.cancer.gov/about‐cancer/treatment/clinical‐trials</a>) </p> </li> </ul> </p> <p>If we had identified any ongoing trials that had not been published, we would have approached the principal investigators and major co‐operative groups active in this area, to ask for relevant data<i>.</i> </p> <p>We handsearched the citation lists of included studies, key textbooks, and previous systematic reviews, and contacted experts in the field to identify further reports of trials. We also handsearched conferences abstracts from the following sources. </p> <p> <ul id="CD012559-list-0007"> <li> <p>Gynecologic Oncology (Annual Meeting of the American Society of Gynecologic Oncology)</p> </li> <li> <p>International Journal of Gynecological Cancer (Annual Meeting of the International Gynecologic Cancer Society) </p> </li> <li> <p>British Gynaecological Cancer Society (BGCS)</p> </li> <li> <p>Annual Meeting of European Society of Gynaecological Oncology (ESGO)</p> </li> </ul> </p> </section> </section> <section id="CD012559-sec-0054"> <h3 class="title" id="CD012559-sec-0054">Data collection and analysis</h3> <section id="CD012559-sec-0055"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database (<a href="http://endnote.com/" target="_blank">Endnote</a>). After duplicates were removed, we transferred these data to <a href="https://www.covidence.org" target="_blank">Covidence</a> for study selection. Two review authors (NS and RB) examined the remaining references independently. We excluded those studies which clearly did not meet the inclusion criteria. We obtained copies of the full text of potentially relevant references. Two review authors (NS and RB) independently assessed the eligibility of the retrieved reports/publications. We resolved any disagreement through discussion and we consulted a third person (TL) for a final decision. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (<a href="./references#CD012559-bbs2-0033" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6:e1000100. ">Liberati 2009</a>). </p> </section> <section id="CD012559-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (NS and KP) independently extracted study characteristics and outcome data from included studies to a piloted data collection form, using <a href="https://www.covidence.org" target="_blank">Covidence</a>. We noted in the <a href="./references#CD012559-sec-0116" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third person (RB). One review author (NS) transferred data into the Review Manager 5 (<a href="./references#CD012559-bbs2-0047" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) file. We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (KP) spot‐checked study characteristics for accuracy against the trial report. </p> <p>For included studies, we extracted the following details.</p> <p> <ul id="CD012559-list-0008"> <li> <p>Author, year of publication and journal citation (including language)</p> </li> <li> <p>Country</p> </li> <li> <p>Setting</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Study design, methodology</p> </li> <li> <p>Study population</p> <ul id="CD012559-list-0009"> <li> <p>Total number enrolled</p> </li> <li> <p>Participant characteristics: age, menopausal status at diagnosis, performance status</p> </li> <li> <p>Treatment: type of surgery and chemotherapy</p> </li> <li> <p>Tumour stage, grade and types</p> </li> </ul> </li> </ul> <ul id="CD012559-list-0010"> <li> <p>Intervention details</p> <ul id="CD012559-list-0011"> <li> <p>All types of HRT: oestrogen alone or combined with progestin, oestrogen agonist/antagonist, progestin, or testosterone, and tibolone </p> </li> <li> <p>Duration of administration of HRT in years</p> </li> <li> <p>Route and doses of HRT</p> </li> </ul> </li> </ul> <ul id="CD012559-list-0012"> <li> <p>Comparison</p> <ul id="CD012559-list-0013"> <li> <p>Placebo or no treatment</p> </li> </ul> </li> <li> <p>Risk of bias in study (see <a href="#CD012559-sec-0057">Assessment of risk of bias in included studies</a>) </p> </li> <li> <p>Duration of follow‐up</p> </li> <li> <p>Outcomes: for each outcome, we extracted the outcome definition. For adjusted estimates, we recorded variables adjusted for in analyses. </p> </li> <li> <p>Results: we extracted the number of participants allocated to each intervention group, the total number analyzed for each outcome and number of dropouts, including reason for leaving the study. </p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Outcome data were extracted as follows.</p> <p> <ul id="CD012559-list-0014"> <li> <p>For time‐to‐event data (survival and disease progression), we extracted the log of the hazard ratio (log(HR)) and its standard error from trial reports. For those studies that they did not report the HR, we attempted to estimate HR, the observed minus expected events (O‐E) and the variance (V) using formula according to <a href="./references#CD012559-bbs2-0056" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. BioMed Central2007;8:1‐16. ">Tierney 2007</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events or deaths) we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, in order to estimate a risk ratio. </p> </li> <li> <p>For continuous outcomes (e.g. quality‐of‐life measures), we extracted the final value and standard deviation of the outcome of interest and the number of participants assessed at endpoint in each treatment arm at the end of follow‐up, in order to estimate the mean difference between treatment arms and its standard error. </p> </li> </ul> </p> <p>Where possible, all data extracted would be those relevant to an intention‐to‐treat analysis, in which participants would be analyzed in groups to which they were assigned. We noted the time points at which outcomes were collected and reported. </p> </section> <section id="CD012559-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NS and KP) applied the Cochrane 'Risk of bias' tool independently and resolved differences by discussion or by appeal to a third review author (EM). We judged each item as being at high, low or unclear risk of bias, as set out in the criteria provided by <a href="./references#CD012559-bbs2-0024" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook. ">Higgins 2011</a> (and shown below), and provided a quote from the study report and/or a statement as justification for the judgement for each item in the 'Risk of bias' table. We summarized results in both a 'Risk of bias' graph and a 'Risk of bias' summary. When interpreting treatment effects and meta‐analyses, we took into account the risk of bias for the studies that contributed to that outcome. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p> <ul id="CD012559-list-0015"> <li> <p>Random sequence generation</p> <ul id="CD012559-list-0016"> <li> <p>Low risk of bias: e.g. participants were assigned to treatments on basis of a computer‐generated random sequence or a table of random numbers </p> </li> <li> <p>High risk of bias: e.g. participants were assigned to treatments on basis of date of birth, clinic ID number or surname, or there was no attempt to randomize participants </p> </li> <li> <p>Unclear risk of bias: e.g. sequence generation not reported or the information was not available </p> </li> </ul> </li> <li> <p>Allocation concealment</p> <ul id="CD012559-list-0017"> <li> <p>Low risk of bias: e.g. where the allocation sequence could not be foretold</p> </li> <li> <p>High risk of bias: e.g. the allocation sequence could be foretold by participants, investigators or treatment providers </p> </li> <li> <p>Unclear risk of bias: e.g. allocation concealment was not reported</p> </li> </ul> </li> <li> <p>Blinding of participants and personnel</p> <ul id="CD012559-list-0018"> <li> <p>Low risk of bias if participants and personnel were adequately blinded</p> </li> <li> <p>High risk of bias if participants were not blinded to the intervention that the participant received </p> </li> <li> <p>Unclear risk of bias if this was not reported or unclear</p> </li> </ul> </li> <li> <p>Blinding of outcomes assessors</p> <ul id="CD012559-list-0019"> <li> <p>Low risk of bias if outcome assessors were adequately blinded</p> </li> <li> <p>High risk of bias if outcome assessors were not blinded to the intervention that the participant received </p> </li> <li> <p>Unclear risk of bias if this was not reported or unclear</p> </li> </ul> </li> <li> <p>Incomplete outcome data: we recorded the proportion of participants whose outcomes were not reported at the end of the study. We coded a satisfactory level of loss to follow‐up for each outcome as follows. </p> <ul id="CD012559-list-0020"> <li> <p>Low risk of bias if fewer than 20% of participants were lost to follow‐up and reasons for loss to follow‐up were similar in both treatment arms </p> </li> <li> <p>High risk of bias if more than 20% of participants were lost to follow‐up or reasons for loss to follow‐up differed between treatment arms </p> </li> <li> <p>Unclear risk of bias if loss to follow‐up was not reported</p> </li> </ul> </li> <li> <p>Selective reporting of outcomes</p> <ul id="CD012559-list-0021"> <li> <p>Low risk of bias: e.g. the study reported all outcomes specified in the protocol</p> </li> <li> <p>High risk of bias: e.g. it was suspected that outcomes had been selectively reported</p> </li> <li> <p>Unclear risk of bias: e.g. it was unclear whether outcomes had been selectively reported</p> </li> </ul> </li> </ul> <ul id="CD012559-list-0022"> <li> <p>Other biases</p> <ul id="CD012559-list-0023"> <li> <p>Low risk of bias: if we did not suspect any other source of bias and the trial appeared to be methodologically sound </p> </li> <li> <p>High risk of bias: if we suspected that the trial had been prone to an additional bias </p> </li> <li> <p>Unclear risk of bias: if we are uncertain whether an additional bias might had been present </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012559-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD012559-list-0024"> <li> <p>For time‐to‐event data, we used the hazard ratio.</p> </li> <li> <p>For dichotomous outcomes, we analyzed data based on the number of events and the number of people assessed in the intervention and comparison groups. We used these to calculate the risk ratio and 95% confidence interval (CI). </p> </li> <li> <p>For continuous outcomes, we analyzed data based on the mean, standard deviation and number of people assessed for both the intervention and comparison groups to calculate mean difference between treatment arms, with a 95% CI. If the mean difference was reported without individual group data, we planned to use this to report the study results<i>.</i> If more than one study measured the same outcome using different tools, we planned to calculate the standardized mean difference and 95% CI using the inverse variance method in <a href="./references#CD012559-bbs2-0047" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. </p> </li> </ul> </p> </section> <section id="CD012559-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>If any trials with multiple treatment groups had been identified, we would have divided the ‘shared’ comparison group into the number of treatment groups and comparisons between each treatment group and treated the split comparison group as independent comparisons. </p> </section> <section id="CD012559-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We did not contact study authors to obtain missing data (participant, outcome or summary data). We reported on the levels of loss to follow‐up and assessed this as a source of potential bias. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. We did not impute missing outcome data for the primary outcome. </p> </section> <section id="CD012559-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the degree of heterogeneity among trials using I<sup>2</sup> (<a href="./references#CD012559-bbs2-0023" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;357:557‐60. ">Higgins 2003</a>) and Chi<sup>2</sup> statistics (<a href="./references#CD012559-bbs2-0017" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London (UK): BMJ Publication Group, 2001. ">Deeks 2001</a>). We regarded heterogeneity to be substantial if I² was greater than 50% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi<sup>2</sup> test for heterogeneity. If substantial heterogeneity was found, we would have used subgroup and sensitivity analyses to explore the causes of heterogeneity. </p> </section> <section id="CD012559-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>If we identify more than ten studies in future updates of this review, we will examine funnel plots corresponding to meta‐analysis of the primary outcome to assess the potential for small‐study effects such as publication bias. We plan to assess funnel plot asymmetry visually, and if asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD012559-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 (<a href="./references#CD012559-bbs2-0047" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a fixed‐effect model for combining data if there was no substantial heterogeneity. If substantial statistical heterogeneity was detected, we used a random‐effects meta‐analysis to produce an overall summary and the results were presented as the average treatment effect with 95% CIs (<a href="./references#CD012559-bbs2-0018" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). </p> <p> <ul id="CD012559-list-0025"> <li> <p>For time‐to‐event data, we pooled hazard ratios using the generic inverse variance facility of <a href="./references#CD012559-bbs2-0047" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>. </p> </li> <li> <p>For dichotomous outcomes, we calculated the risk ratio for each study and then pooled them. </p> </li> <li> <p>For continuous outcomes, we pooled the mean differences between the treatment arms at the end of follow‐up, where all trials measured the outcome on the same scale; otherwise we planned to pool standardized mean differences. </p> </li> </ul> </p> <p>When we were unable to pool the data statistically using meta‐analysis we conducted a narrative synthesis of results. We presented the major outcomes and results, organised by intervention categories according to the major types or aims (or both) of the identified interventions. Depending on the assembled research, we may also in future explore the possibility of organising the data by population. Within the data categories we will explore the main comparisons of the review. </p> <p>We presented the overall quality of the evidence for each outcome listed below, using the GRADE approach, which took into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results (<a href="./references#CD012559-bbs2-0029" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchunemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;23(2):81. ">Langendam 2013</a>)<i>.</i> We created a 'Summary of findings' table based on the methods described Chapter 12.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012559-bbs2-0051" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlaziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from training.cochrane.org/handbook. ">Schunemann 2011</a>), using <a href="http://gradepro.org/" target="_blank">GRADEpro GDT</a>. We used the checklist to maximize consistent GRADE decisions and the GRADE Working Group quality of evidence definitions (<a href="./references#CD012559-bbs2-0041" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>). We downgraded the evidence from 'high' quality by one level for serious limitations (or two levels for very serious limitations) for each outcome, and outlined our rationale in the footnotes. </p> <p> <ul id="CD012559-list-0026"> <li> <p>High quality: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low quality: we were very uncertain about the estimate.</p> </li> </ul> </p> <p>We included the following outcomes included in the 'Summary of findings' table.</p> <p> <ol id="CD012559-list-0027"> <li> <p>Overall survival</p> </li> <li> <p>Quality of life assessment</p> </li> <li> <p>Progression‐free survival</p> </li> <li> <p>Adverse events</p> <ol id="CD012559-list-0028"> <li> <p>Incidence of breast cancer</p> </li> <li> <p>Incidence of thromboembolic events (DVT/ PE, stroke, MI)</p> </li> <li> <p>Incidence of gallstones</p> </li> </ol> </li> </ol> </p> </section> <section id="CD012559-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not identify any substantial heterogeneity; therefore subgroup analysis were not conducted. In future updates, if more studies are included and substantial heterogeneity is identified, it will be of clinical interest to investigate the safety (risk and benefits) for the prespecified outcomes in this protocol for the following factors. </p> <p> <ul id="CD012559-list-0029"> <li> <p>Menopausal status at diagnosis: premenopausal versus postmenopausal. If menopausal status is not extractable from studies, we will instead analyze by age (under 50 years versus 50 years or older). </p> </li> <li> <p>Hysterectomy versus no hysterectomy.</p> </li> <li> <p>Stage of cancer: stage I to II versus stage III to IV</p> </li> <li> <p>Tumour types: endometrioid versus non‐endometrioid</p> </li> <li> <p>Positive or negative oestrogen receptor, progesterone receptor or BRCA mutation status.</p> </li> </ul> </p> </section> <section id="CD012559-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>If necessary in any future update, we will use sensitivity analyses to assess the cause of substantial heterogeneity by omitting the studies with at a high risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012559-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012559-sec-0066"></div> <section id="CD012559-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD012559-sec-0068"> <h4 class="title">Results of the search</h4> <p>We searched for references up to June 2019. We found 2617 references which met our search criteria, of which 29 were duplicates. Two review authors (NS and RB) independently screened titles and abstracts; the majority of references identified were not RCTs or the objective of study was to investigate the efficacy of hormones on therapeutic outcomes of ovarian cancer and not the effect of HRT. We reviewed 11 full‐text references and excluded eight as they did not meet the inclusion criteria. We identified three studies for inclusion (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>) (see PRISMA flow diagram; <a href="#CD012559-fig-0001">Figure 1</a><i>).</i> </p> <div class="figure" id="CD012559-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012559-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012559-sec-0069"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD012559-sec-0116" title="">Characteristics of included studies</a>. </p> <section id="CD012559-sec-0070"> <h5 class="title">Study location and setting</h5> <p>One study (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>) included women from multiple centres in the United Kingdom, Spain and Hungary, whereas <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> and <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> included single institutes in South Africa and China, respectively. </p> </section> <section id="CD012559-sec-0071"> <h5 class="title">Participants</h5> <p>All women with a diagnosis of EOC had received cytoreductive surgery, chemotherapy, or both, and were well balanced across the two arms of the studies for demographic data. <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> included 150 women with a median age of 58.7 years (and an age range of 29.3 to 89.6 years) and both pre and postmenopausal women were eligible for inclusion. <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> included 130 women aged 59 years or younger, 44% of whom were between 56 and 59 years of age. <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> included 90 women aged 45 years or younger (age range: 20 to 45 years). </p> <p>The number of women that were lost to follow‐up were 0, 5 and 15 participants in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>, <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> and <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>, respectively. Two studies included all stages and histological types (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>), whereas <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> included only International Federation of Gynecology and Obstetrics (FIGO) stage I to III and serous and mucinous type. The majority of tumours were grade 3 in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> and grade 1 in <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>. There were no data on tumour grade in <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>. Participants were randomized to HRT versus no HRT arms using computer‐generated (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>) or sealed‐envelope randomization (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). </p> <p>The women that were excluded from studies were those who had conservative surgery to preserve their ovarian function, had history of hormone‐dependent malignancy with contraindications to hormone therapy (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>), or had low malignant potential and had never taken hormone therapy (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>). </p> <p>None of the studies looked into the effect of BRCA status and HRT effects on survival in women with ovarian cancer. Oestrogen and progesterone receptors were investigated only in one study (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). </p> </section> <section id="CD012559-sec-0072"> <h5 class="title">Interventions</h5> <p>The three included studies used a variety of HRT. <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> used only conjugated oestrogen (0.625 mg/day). <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> used combined HRT: conjugated oestrogen (0.625 mg/day) with medroxyprogesterone (4 mg/day) and nylestriol (2.5 mg/15 day) with medroxyprogesterone (4 mg/day). <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> used oestrogen only: conjugated oestrogen, estradiol patch and estradiol implant, and combined with progesterone; conjugate oestrogen and norgestrel. </p> </section> <section id="CD012559-sec-0073"> <h5 class="title">Outcomes</h5> <p>The median follow‐up time was 31.4 months, 90 months and 19.1 years for <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>, <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> and <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>, respectively. There were participants who were lost to follow‐up: 3.8% in <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> and 16.7% in <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>. These participants were excluded from the analysis and results. In <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>, where the median follow‐up was 19.1 years, 63.9% of participants discontinued hormone therapy; the most common being the presence of adverse effects or unknown reason. </p> <p>There were participants who were assigned to HRT, but did not receive or discontinued HRT (65.5% in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> and 13.6 % in <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>). There were also participants who were assigned to no HRT, but who received HRT (10.7% in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> and 8.5% in <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>). However, all analyses were performed on an intention‐to‐treat basis for these studies. </p> <p>Overall survival was the primary outcome in all three studies. The incidence of breast cancer was studied in two studies (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). Treatment adverse effects and quality of life (using the EORTC‐C30 questionnaire and GMU‐Gynae Index), were only studied in <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>. The EORTC‐C30 was used to assess five function domains (physical, emotional, social, role and cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhoea, insomnia, dyspnoea and loss of appetite) and global health/quality of life. The GMU‐Gynae Index assessed quality of sexual life (sexual difficulties, emotional exchange between the couple, regression of sexual life and sexual desire), symptoms of lower urinary tract infection (urethral burning and frequent urination), autonomic dysfunction (itchy skin, dry skin and formication). The incidence of gallstones was not reported in any study. </p> </section> <section id="CD012559-sec-0074"> <h5 class="title">Dates of study, funding sources and declarations of interest</h5> <p>For <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a> the study period was four to seven years and included participants between January 1987 and June 1994. <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> included participants between February 1990 and November 1995; and <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> included participants between August 1999 and June 2003. </p> <p>Funding was provided by their own institute in two studies<i>(</i><a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>); these studies did not provided details of any conflict of interest. Funding for <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> was provided from multiple sources as this was a multicentre study; they declared conflicts of interest among the various authors. </p> </section> </section> <section id="CD012559-sec-0075"> <h4 class="title">Excluded studies</h4> <p>We excluded eight references from the full‐text review, of which three were duplicate reports (<a href="./references#CD012559-bbs2-0006" title="GuidozziF . Hormone replacement therapy in patients with ovarian cancer. The 29th Congress of the South African Society of Obstetrics and Gynecology 8‐12 March 1998:XAOC ‐ LTE 1998; 29‐XPH ‐ N1998. ">Guidozzi 1998</a>; <a href="./references#CD012559-bbs2-0007" title="GuidozziF , PaponteA . Estrogen replacement therapy in ovarian cancer survivors. International journal of gynecological cancer1999;9 Suppl 1 XPH ‐ Y(Suppl 1):5:Abstract A13. ">Guidozzi 1999a</a>; <a href="./references#CD012559-bbs2-0009" title="LiL , PanZM , ChenXQ , GaoK , ZhangW , LuoY , et al. Relationship between hormone therapy in women with ovarian malignancy and prognosis. Chung‐Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp; Gynecology]2008;43(11):843‐8. ">Li 2008</a>), two were non‐randomized studies (<a href="./references#CD012559-bbs2-0005" title="BebarS , Ursic‐VrscajM . Hormone replacement therapy after epithelial ovarian cancer treatment. European Journal of Gynaecological Oncology2000;21(2):192‐6. ">Bebar 2000</a>; <a href="./references#CD012559-bbs2-0011" title="Ursic‐VrscajM , BebarS , ZakeljMP . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause2001;8(1):70‐5. ">Ursic‐Vrscaj 2001</a>), two were literature reviews (<a href="./references#CD012559-bbs2-0008" title="GuidozziF . Estrogen therapy in gynecological cancer survivors. Climacteric2013;16(6):611‐7. ">Guidozzi 2013</a>; <a href="./references#CD012559-bbs2-0010" title="LipkowitzS , KohnEC . To treat or not to treat: the use of hormone replacement therapy in patients with ovarian cancer. Journal of Clinical Oncology2015;33(35):4127‐8. ">Lipkowitz 2015</a>), and one was a study which included healthy postmenopausal women (<a href="./references#CD012559-bbs2-0004" title="AndersonGL , JuddHL , KaunitzAM , BaradDH , BeresfordSA , PettingerM , et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. Journal of the American Medical Association2003;290(13):1739‐48. ">Anderson 2003</a>). See <a href="./references#CD012559-sec-0117" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012559-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>The details of risk of bias for the three included studies are shown in <a href="#CD012559-fig-0002">Figure 2</a> and <a href="#CD012559-fig-0003">Figure 3</a><i>.</i> </p> <div class="figure" id="CD012559-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012559-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012559-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012559-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012559-sec-0077"> <h4 class="title">Allocation</h4> <p>Three studies used randomization for allocation; one study clearly described using computer‐generated random permuted blocks (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>) and the other two did not mention the method used (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). </p> <p>Two studies showed adequate allocation concealment using central randomization (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>) or sealed opaque envelopes (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>); and one study had insufficient information to justify a judgement of low or high risk of bias (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). </p> </section> <section id="CD012559-sec-0078"> <h4 class="title">Blinding</h4> <p>All studies had a high risk of performance bias because the participants knew the HRT they were receiving and there was no placebo used. There was no information about the assessors and whether they knew the treatment group in all three studies; therefore we classified the risk of detection bias as unclear. </p> </section> <section id="CD012559-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>All three studies reported data on losses to follow‐up and non‐compliance (0% and 65.3%, respectively in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; and 3.8% and 31.1%, respectively in <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>); however, they analyzed their results on an intention‐to‐treat basis. <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a> excluded from analysis participants who were lost to follow‐up or non‐compliance to HRT within six months (16.7%). </p> </section> <section id="CD012559-sec-0080"> <h4 class="title">Selective reporting</h4> <p>The study protocols were not available, however, the studies reported the results as detailed in their objectives. </p> </section> <section id="CD012559-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>The studies appeared to be free of other sources of bias.</p> </section> </section> <section id="CD012559-sec-0082"> <h3 class="title" id="CD012559-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD012559-tbl-0001"><b>Summary of findings for the main comparison</b> Hormone replacement therapy (HRT) compared to no HRT for women who have undergone surgery for epithelial ovarian cancer (EOC)</a> </p> <p>See <a href="./full#CD012559-tbl-0001">summary of findings Table for the main comparison</a>: HRT versus no HRT for women who have undergone surgical treatment for EOC. </p> <section id="CD012559-sec-0083"> <h4 class="title">Primary outcomes</h4> <section id="CD012559-sec-0084"> <h5 class="title">Overall survival</h5> <p>All three studies reported overall survival. The pooled result showed that HRT may improve overall survival in women who have had surgery for EOC (HR 0.71, 95% CI 0.54 to 0.93; three studies, 350 participants; low‐certainty evidence; <a href="./references#CD012559-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD012559-sec-0085"> <h5 class="title">Quality of life</h5> <p>We are uncertain whether HRT improves or reduces the overall quality of life women who have had surgery for EOC (MD 13.67 points higher; 95% CI 9.26 higher to 18.08 higher; very low‐certainty evidence; one study, 75 participants; very low‐certainty evidence; <a href="./references#CD012559-fig-0005" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD012559-sec-0086"> <h4 class="title">Secondary outcome</h4> <section id="CD012559-sec-0087"> <h5 class="title">Progression‐free survival</h5> <p>The effect of HRT on progression‐free survival in women who have had surgery for EOC was assessed in two studies (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>); the range where the actual effect may be (the "margin of error") indicated that it may make little or no difference (HR 0.76, 95% CI 0.57 to 1.01; two studies, 275 participants; low‐certainty evidence; <a href="./references#CD012559-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012559-sec-0088"> <h5 class="title">Incidence of breast cancer</h5> <p>It is uncertain whether HRT increased the incidence of breast cancer. There were only three participants who developed breast cancer: two participants in the HRT arm, and one participant in the no HRT arm, in one study (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>); and none in another study (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). The effect of HRT varied and it was possible that HRT made little or no difference as we are very uncertain of the results (RR 2.00, 95% CI 0.19 to 21.59; two studies, 225 participants; very low‐certainty evidence; <a href="./references#CD012559-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012559-sec-0089"> <h5 class="title">Transient ischaemic attack (TIA)</h5> <p>It was very uncertain whether HRT increases the incidence of TIA. There were only two participants who developed TIA in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>, both in the HRT arm (RR 5.00, 95% CI 0.24 to 102.42; one study, 150 participants; very low‐certainty evidence; <a href="./references#CD012559-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD012559-sec-0090"> <h5 class="title">Cerebrovascular accident (CVA)</h5> <p>It was uncertain whether HRT decreases the incidence of CVA. There were five participants who developed CVA in one study (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>): two participants in the HRT arm and three participants in the no HRT arm (RR 0.67; 95% CI 0.11 to 3.88; one study, 150 participants; very low‐certainty evidence; <a href="./references#CD012559-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD012559-sec-0091"> <h5 class="title">Myocardial infarction (MI)</h5> <p>It was uncertain whether HRT decreases the incidence of MI. There were two participants in <a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a> who developed MI, both in the no HRT arm (RR 0.20, 95% CI 0.01 to 4.10; one study, 150 participants; very low‐certainty evidence; <a href="./references#CD012559-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD012559-sec-0092"> <h5 class="title">Incidence of gallstone</h5> <p>The incidence of gallstone was not reported in any of the included studies.</p> </section> </section> <section id="CD012559-sec-0093"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p>We did not perform subgroup or sensitivity analyses for any outcomes due to there only being a small number of trials and no substantial heterogeneity identified. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012559-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012559-sec-0094">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012559-sec-0147">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012559-sec-0094"></div> <section id="CD012559-sec-0095"> <h3 class="title" id="CD012559-sec-0095">Summary of main results</h3> <p>The evidence on the efficacy and safety of HRT versus no HRT in women who have undergone surgical treatment for EOC is limited; only three small studies met the inclusion criteria for our review and they provided low‐ to very low‐certainty evidence. Quality of life, measured using EORTC‐C30 scale, was presented only in one study (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). HRT may slightly improve overall survival in women who have had surgical treatment for EOC, but may make little or no difference to quality of life, progression‐free survival, incidence of breast cancer, transient ischaemic accident, cerebrovascular accident and myocardial infarction events. </p> </section> <section id="CD012559-sec-0096"> <h3 class="title" id="CD012559-sec-0096">Overall completeness and applicability of evidence</h3> <p>All published RCTs that were included in this meta‐analysis reported outcomes for all the outcomes of this review, except the incidence of gallstones. We found that HRT may slightly improve overall survival and quality of life in women after oncological treatment for EOC. </p> <p>One of the included trials was conducted across European centres including the United Kingdom, Spain and Hungary (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>), while the other two were single‐centre trials in South Africa (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>) and Asia (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). All three studies reported on overall survival; two reported progression‐free survival (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>) and incidence of breast cancer <b>(</b><a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). Adverse effects were only reported in one study, the results for which had wide confidence intervals influenced by the small sample size (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>). </p> <p>The EORTC‐C30 questionnaire was used for quality‐of‐life assessments in <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>, and we selected only the domain of general condition in this questionnaire for analysis. EORTC‐C30 is a standardized questionnaire commonly used for people with cancer (<a href="./references#CD012559-bbs2-0055" title="SnyderCF , BlackfordAL , OkuyamaT , AkechiT , YamashitaH , ToyamaT , et al. Using the EORTC‐QLQ‐C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Quality of Life Research2013;22:2685‐91. ">Snyder 2013</a>), not a menopause‐specific assessment. The Menopause Specific Quality of Life Questionnaire (MENQOL), World Health Organization Quality of Life (WHO QOL‐BREF), Greene Climacteric Scale, Utian Quality of Life (UQOL) Scale, Women's Health Questionnaire (WHQ), 36‐Item Short Form (SF‐36), MENCAV, Cervantes Scale, Cervantes Short‐Form Scale, and Menopause Rating Scale (MRS) are the questionnaires that can be used to specifically assess menopausal symptoms (<a href="./references#CD012559-bbs2-0028" title="JenabiE , ShobeiriF , HazaveheiSMM , RoshanaeiG . Assessment of questionnaire measuring quality of life in menopausal women: a systematic review. Oman Medical Journal2015;30(3):151‐6. ">Jenabi 2015</a>)<b>.</b> </p> <p>Hormone replacement therapy may increase the risk of developing other diseases such as breast cancer, when combined hormonal therapy is used (<a href="./references#CD012559-bbs2-0012" title="BenkhadraK , MohammedK , NofalAA , LeonBC , AlahdabF , FaubionS , et al. Menopausal hormone therapy and mortality: a systematic review and meta‐analysis. Journal of Clinical Endocrinology &amp; Metabolism2015;100(11):4021‐8. ">Benkhadra 2015</a>; <a href="./references#CD012559-bbs2-0016" title="ChlebowskiRT , RohanTE , MansonJE , AragakiAK , KaunitzA , StefanickML , et al. Breast cancer after use of estrogen plus progestin and estrogen alone; analyses of data from 2 Women's Health Initiative randomized clinical trials. Journal of the American Medical Association2015;1(3):296‐305. ">Chlebowski 2015</a>; <a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>), coronary heart disease (<a href="./references#CD012559-bbs2-0049" title="RossouwJE , AndersonGL , PrenticeRL , LaCroixAZ , KooperbergC , StefanickML , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association2002;288(3):321‐33. ">Rossouw 2002</a>; <a href="./references#CD012559-bbs2-0050" title="RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Journal of the American Medical Association2007;297(13):1465‐77. ">Rossouw 2007</a>), stroke (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>; <a href="./references#CD012559-bbs2-0049" title="RossouwJE , AndersonGL , PrenticeRL , LaCroixAZ , KooperbergC , StefanickML , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association2002;288(3):321‐33. ">Rossouw 2002</a>), pulmonary embolism (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>; <a href="./references#CD012559-bbs2-0049" title="RossouwJE , AndersonGL , PrenticeRL , LaCroixAZ , KooperbergC , StefanickML , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association2002;288(3):321‐33. ">Rossouw 2002</a>), deep vein thrombosis (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>), dementia (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>) and gallbladder disease (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>). Prolonged use of HRT and the use of combined HRT for women older than 60 years of age has been associated with higher risk of developing pulmonary embolism and lower risk of colorectal cancer. Women who have undergone hysterectomy who use oestrogen‐only HRT may have an increased risk of stroke and colorectal cancer, when older than 60 and 70 years of age, respectively (<a href="./references#CD012559-bbs2-0037" title="MansonJE , ChlebowskiRT , StefanickML , AragakiAK , RossouwJE , PrenticeRL , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association2013;310(13):1353‐68. ">Manson 2013</a>). The use of HRT in healthy postmenopausal women has been associated with increased risk of developing ovarian cancer (<a href="./references#CD012559-bbs2-0048" title="RodriguezC , PatelAV , CalleEE , JacobEJ , ThunMJ . Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association2001;285(11):1460‐5. ">Rodrigguez 2001</a>; <a href="./references#CD012559-bbs2-0060" title="ZhouB , SunQ , CongR , GuH , TangN , YangL , et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology2008;108(3):641‐51. ">Zhou 2008</a>), of both serous (<a href="./references#CD012559-bbs2-0015" title="Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‐analysis of 52 epidemiological studies. Lancet2015;385:1835‐42. ">Cancer Epidemiology 2015</a>; <a href="./references#CD012559-bbs2-0044" title="MørchLS , LøkkegaardE , AndreasenAH , KjærSK , LidegaardØ . Hormone therapy and different ovarian cancers: a National Cohort Study. American Journal of Epidemiology2012;175(12):1234‐42. ">Mørch 2012</a>; <a href="./references#CD012559-bbs2-0053" title="ShiLF , WuY , LiCY . Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta‐analysis. Menopause2015;23(4):417‐24. ">Shi 2015</a>) and endometrioid types (<a href="./references#CD012559-bbs2-0015" title="Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‐analysis of 52 epidemiological studies. Lancet2015;385:1835‐42. ">Cancer Epidemiology 2015</a>; <a href="./references#CD012559-bbs2-0044" title="MørchLS , LøkkegaardE , AndreasenAH , KjærSK , LidegaardØ . Hormone therapy and different ovarian cancers: a National Cohort Study. American Journal of Epidemiology2012;175(12):1234‐42. ">Mørch 2012</a>). Using HRT for more than five years is linked to increased risk of ovarian cancer (<a href="./references#CD012559-bbs2-0060" title="ZhouB , SunQ , CongR , GuH , TangN , YangL , et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology2008;108(3):641‐51. ">Zhou 2008</a>) and this correlation is stronger for the serous type (<a href="./references#CD012559-bbs2-0044" title="MørchLS , LøkkegaardE , AndreasenAH , KjærSK , LidegaardØ . Hormone therapy and different ovarian cancers: a National Cohort Study. American Journal of Epidemiology2012;175(12):1234‐42. ">Mørch 2012</a>). </p> <p>Hormone receptors, oestrogen receptors or progesterone receptors and BRCA mutation status are known prognostic factors in ovarian cancer ( <a href="./references#CD012559-bbs2-0035" title="LuoH , LiS , ZhaoM , ShengB , ZhuH , ZhuX . Prognostic value of progesterone receptor expression in ovarian cancer: a meta‐analysis. Oncotarget2017;8(22):36845‐56. ">Luo 2017</a>; <a href="./references#CD012559-bbs2-0052" title="ShenZ , LuoH , LiS , ShengB , ZhaoM , ZhuH , et al. Correlation between estrogen receptor expression and prognosisin epithelial ovarian cancer: a meta‐analysis. Oncotarget2017;8(37):62400‐13. ">Shen 2017</a>; <a href="./references#CD012559-bbs2-0059" title="ZhongQ , PengHL , ZhaoX , ZhangL , HwangWT . Effects of BRCA1‐ and BRCA2‐related mutations on ovarian and breast cancer survival: a meta‐analysis. Clinical Cancer Research2015;21(1):211‐20. ">Zhong 2015</a>). The presence of oestrogen receptors has been associated with favourable overall survival in women with unclassified EOC in Europe, South America and Oceania. However, oestrogen receptors have not been associated with a longer progression‐free survival (<a href="./references#CD012559-bbs2-0052" title="ShenZ , LuoH , LiS , ShengB , ZhaoM , ZhuH , et al. Correlation between estrogen receptor expression and prognosisin epithelial ovarian cancer: a meta‐analysis. Oncotarget2017;8(37):62400‐13. ">Shen 2017</a>). The presence of progesterone receptors has also been associated with favourable overall survival and progression‐free survival in European women with unclassified EOC (<a href="./references#CD012559-bbs2-0035" title="LuoH , LiS , ZhaoM , ShengB , ZhuH , ZhuX . Prognostic value of progesterone receptor expression in ovarian cancer: a meta‐analysis. Oncotarget2017;8(22):36845‐56. ">Luo 2017</a>). Likewise, BRCA mutation has been correlated to better overall and progression‐free survival (<a href="./references#CD012559-bbs2-0059" title="ZhongQ , PengHL , ZhaoX , ZhangL , HwangWT . Effects of BRCA1‐ and BRCA2‐related mutations on ovarian and breast cancer survival: a meta‐analysis. Clinical Cancer Research2015;21(1):211‐20. ">Zhong 2015</a>). However, no studies were identified that looked at the effect of HRT in women who have undergone surgical treatment for EOC with hormone receptors or BRCA mutation. </p> <p>We did not identified heterogeneity of outcomes among the various studies. There was no studies comparing the different regimens and duration of HRT, although there were variations in the age and race of participants, stage and histological type of disease, regimen, dose and route of administration for HRT. This may indicate the generalisability of the application in clinical practice. However, the information on duration of HRT use, hormone receptor status and BRCA mutation was limited. </p> </section> <section id="CD012559-sec-0097"> <h3 class="title" id="CD012559-sec-0097">Quality of the evidence</h3> <p>Using the GRADE system, we estimated the certainty of the evidence to be low because of limitations in the design of the included studies design and inconsistency of results. Not all studies had used placebo in the control group; participants knew what hormone therapy they received and in some studies, there was loss to follow‐up greater than 20% (<a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>). There were also differences in the outcomes; one study showed an effect of HRT use (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>), whereas the others did not show the same effect (or only partly in one study (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>)). The GRADE rating was further downgraded to very low‐certainty evidence due to imprecision of results, small sample sizes and wide 95% CIs. </p> </section> <section id="CD012559-sec-0098"> <h3 class="title" id="CD012559-sec-0098">Potential biases in the review process</h3> <p>We conducted a comprehensive search of the available evidence. Two review authors independently searched for studies following clear inclusion and exclusion criteria and identified eligible studies. Two review authors independently extracted data and evaluated risk of bias. It remains possible that studies may have not been reported or were missed and not included. Analysis of publication bias could not be performed in this review as the number of included studies is lower than ten. </p> </section> <section id="CD012559-sec-0099"> <h3 class="title" id="CD012559-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>A recent meta‐analysis on the effect of HRT in the general population showed that HRT did not affect the risk of death from cardiac events, stroke and cancer (breast, lung, colorectal or ovarian) (<a href="./references#CD012559-bbs2-0012" title="BenkhadraK , MohammedK , NofalAA , LeonBC , AlahdabF , FaubionS , et al. Menopausal hormone therapy and mortality: a systematic review and meta‐analysis. Journal of Clinical Endocrinology &amp; Metabolism2015;100(11):4021‐8. ">Benkhadra 2015</a>). However, combined HRT use, but not oestrogen‐only HRT, was associated with an increased risk of mortality from breast cancer (<a href="./references#CD012559-bbs2-0012" title="BenkhadraK , MohammedK , NofalAA , LeonBC , AlahdabF , FaubionS , et al. Menopausal hormone therapy and mortality: a systematic review and meta‐analysis. Journal of Clinical Endocrinology &amp; Metabolism2015;100(11):4021‐8. ">Benkhadra 2015</a>). This meta‐analysis examined younger women (who started HRT aged under 60 or within 10 years of menopause) separately and found that HRT use was associated with lower all‐cause mortality. The evidence on HRT in women experiencing natural menopause remains unclear. The findings of a systematic review and meta‐analysis (which included 310,329 women) showed that women experiencing early menopause (at less than 45 years of age) had overall higher incidence of coronary heart disease and mortality from coronary heart disease, cardiovascular disease and all‐cause mortality (<a href="./references#CD012559-bbs2-0043" title="MukaT , Oliver‐WilliamsC , KunutsorS , LavenJS , FauserBC , ChowdhuryR , et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all‐cause mortality: a systematic review and meta‐analysis. Journal of the American Medical Association2016;1(7):767‐76. ">Muka 2016</a>). A large epidemiological study, the Black Women’s Health Study, investigated all‐cause mortality in 11,212 women with natural menopause and found that women aged less than 45 years who never used HRT had a higher mortality rate; this was not significant for those who ever used HRT (<a href="./references#CD012559-bbs2-0031" title="LiS , RosenbergL , WiseLA , BoggsDA , LaValleyM , PalmerJR . Age at natural menopause in relation to all‐cause and cause‐specific mortality in a follow‐up study of U.S. black women. Maturitas2013;75(3):246‐52. ">Li 2013</a>). In another USA‐based epidemiological study of 11,287 women, all‐cause mortality was higher in women experiencing menopause under 45 years of age (<a href="./references#CD012559-bbs2-0036" title="MalekAM , VladutiuCJ , MeyerML , CushmanM , NewmanR , LisabethLD , et al. The association of age at menopause and all‐cause and cause‐specific mortality by race, postmenopausal hormone use, and smoking status. Preventive Medicine Reports2019;15:100955. ">Malek 2019</a>). Over a 7.1 year follow‐up, those experiencing menopause under 45 years who had ever used HRT had a higher all‐cause mortality rate than those who experienced menopause over 45 years of age who had ever used HRT, although limitations include association of smoking with an early age of menopause. In addition, women who used HRT for more than five years, from around the age of 50, were found to have a higher risk of ovarian cancer, especially for serous and endometrioid types (<a href="./references#CD012559-bbs2-0015" title="Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‐analysis of 52 epidemiological studies. Lancet2015;385:1835‐42. ">Cancer Epidemiology 2015</a>). </p> <p>There have been three previous systematic reviews of the use of HRT in EOC after treatment. The first systematic review, <a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>, included one RCT (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>) and two observational studies. The second and third systematic reviews (<a href="./references#CD012559-bbs2-0032" title="LiD , DingC‐y , QiuL‐h . Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology2015;139(2):355‐62. ">Li 2015</a>; <a href="./references#CD012559-bbs2-0046" title="PergialiotisV , PitsouniE , ProdromidouA , FrountzasM , PerreaDN , VlachosGD . Hormone therapy for ovarian cancer survivors: systematic review and meta‐analysis. Menopuase2015;23(3):335‐42. ">Pergialiotis 2015</a>) included two RCTs (<a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>) and four cohort studies. The result of all these systematic reviews showed that HRT may make little or no difference to overall and progression‐free survival. Our review included three RCTs (<a href="./references#CD012559-bbs2-0001" title="EelesRA , MordenJP , GoreM , MansiJ , GleesJ , WenxzlM , et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT Randomized Trial. Journal of Clinical Oncology2015;33(35):4138‐44. [DOI: 10.1200/JCO.2015.60.9719] ">Eeles 2015</a>; <a href="./references#CD012559-bbs2-0002" title="GuidozziF , DaponteA . Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer1999;86(6):1013‐8. ">Guidozzi 1999</a>; <a href="./references#CD012559-bbs2-0003" title="LiL , PanZ , GaoK , ZhangW , LuoY , YaoZ , et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters2012;3(1):244‐9. ">Li 2012</a>) and the results suggest that HRT may be associated with a slight improvement in overall survival and quality of life (especially for general condition), but may make little or no difference to progression‐free survival. The results of adverse events of HRT were not reported in any of the three previous systematic reviews (<a href="./references#CD012559-bbs2-0025" title="HopkinsML , FungMF , LeT , ShorrR . Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology2004;92(3):827‐32. ">Hopkins 2004</a>; <a href="./references#CD012559-bbs2-0032" title="LiD , DingC‐y , QiuL‐h . Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology2015;139(2):355‐62. ">Li 2015</a>; <a href="./references#CD012559-bbs2-0046" title="PergialiotisV , PitsouniE , ProdromidouA , FrountzasM , PerreaDN , VlachosGD . Hormone therapy for ovarian cancer survivors: systematic review and meta‐analysis. Menopuase2015;23(3):335‐42. ">Pergialiotis 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012559-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012559-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012559-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012559-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 1 Overall survival." data-id="CD012559-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 2 Quality of life, general condition." data-id="CD012559-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 2 Quality of life, general condition. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 3 Progression‐free survival." data-id="CD012559-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 3 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 4 Incidence of breast cancer." data-id="CD012559-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 4 Incidence of breast cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 5 Transient ischaemic attack." data-id="CD012559-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 5 Transient ischaemic attack. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 6 Cerebrovascular accident." data-id="CD012559-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 6 Cerebrovascular accident. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012559-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/urn:x-wiley:14651858:media:CD012559:CD012559-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_t/tCD012559-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 7 Myocardial infarction." data-id="CD012559-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hormone replacement therapy versus no hormone replacement therapy, Outcome 7 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/media/CDSR/CD012559/image_n/nCD012559-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012559-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone replacement therapy (HRT) compared to no HRT for women who have undergone surgery for epithelial ovarian cancer (EOC)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hormone replacement therapy (HRT) compared to no HRT for epithelial ovarian cancer (EOC)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patients:</b> women of any age diagnosed with any stage of EOC who had surgical treatment, regardless of chemotherapy treatment<br/> <b>Setting:</b> multiple centres in the United Kingdom, Spain and Hungary, and single institutes in South Africa and China<br/> <b>Intervention:</b> HRT; oestrogen‐alone, and oestrogen combined with progestin, oestrogen agonist/antagonist, testosterone or tibolone in any dose and any route of administration<br/> <b>Comparison:</b> no HRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no HRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.71<br/> (0.54 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>350<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the three included studies was 31.4 months, 90 months and 19.1 years. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>795 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1,000<br/> (575 to 771) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life, general condition</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean quality of life (general condition) in the no HRT group was 13.84 points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean quality of life (general condition) in the HRT group was 13.67 points higher<br/> (9.26 higher to 18.08 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The EORTC‐C30 questionnaire was used to evaluate this outcome; higher values correspond with improvement. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/> (0.57 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the two studies was 90 months and 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>773 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>676 per 1,000<br/> (571 to 776) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of breast cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/> (0.19 to 21.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the two studies was 31.41 months and 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1,000<br/> (2 to 181) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of transient ischaemic attack</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.24 to 102.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (2 to 683) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of cerebrovascular accident</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.11 to 3.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000<br/> (4 to 155) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.01 to 4.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The median follow‐up time in the study was 19.1 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1,000<br/> (0 to 109) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of gallstones</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The incidence of gallstones was not reported in the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; HR: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level due to limitations in study design<br/> <sup>2</sup> Downgraded by one level due to inconsistency of results<br/> <sup>3</sup> Downgraded by one level due to imprecision of results<br/> <sup>4</sup> Downgraded by two levels due to imprecision of results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone replacement therapy (HRT) compared to no HRT for women who have undergone surgery for epithelial ovarian cancer (EOC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/full#CD012559-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012559-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hormone replacement therapy versus no hormone replacement therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.54, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life, general condition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.57, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of breast cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cerebrovascular accident <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hormone replacement therapy versus no hormone replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012559.pub2/references#CD012559-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012559.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012559-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012559-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012559-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012559-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD012559-note-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012559-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012559-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012559\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012559\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012559\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012559\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012559\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012559.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012559.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012559.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012559.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012559.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714007442"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012559.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714007446"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012559.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d642cba19937a',t:'MTc0MDcxNDAwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 